Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 22 (Search time: 0.004 seconds).
previous
1
2
3
next
Item hits:
Preview
Issue Date
Title
Author(s)
2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Druker, B.
;
Guilhot, F.
;
O'Brien, S.
;
Gathmann, I.
;
Kantarjian, H.
;
Gattermann, N.
;
Deininger, M.
;
Silver, R.
;
Goldman, J.
;
Stone, R.
;
Cervantes, F.
;
Hochhaus, A.
;
Powell, B.
;
Gabrilove, J.
;
Rousselot, P.
;
Reiffers, J.
;
Cornelissen, J.
;
Hughes, T.
;
Agis, H.
;
Fischer, T.
;
et al.
2009
Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Two-year follow-up of a randomized phase 2 study (START-R)
Kantarjian, H.
;
Pasquini, R.
;
Levy, V.
;
Jootar, S.
;
Holowiecki, J.
;
Hamerschlak, N.
;
Hughes, T.
;
Bleickardt, E.
;
Dejardin, D.
;
Cortes, J.
;
Shah, N.
2014
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Hughes, T.
;
Saglio, G.
;
Kantarjian, H.
;
Guilhot, F.
;
Niederwieser, D.
;
Rosti, G.
;
Nakaseko, C.
;
De Souza, C.
;
Kalaycio, M.
;
Meier, S.
;
Fan, X.
;
Menssen, H.
;
Larson, R.
;
Hochhaus, A.
2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Hughes, T.
;
Hochhaus, A.
;
Kantarjian, H.
;
Cervantes, F.
;
Guilhot, F.
;
Niederwieser, D.
;
Le Coutre, P.
;
Rosti, G.
;
Ossenkoppele, G.
;
Lobo, C.
;
Shibayama, H.
;
Fan, X.
;
Menssen, H.
;
Kemp, C.
;
Larson, R.
;
Saglio, G.
2016
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Deininger, M.
;
Hodgson, J.
;
Shah, N.
;
Cortes, J.
;
Kim, D.
;
Nicolini, F.
;
Talpaz, M.
;
Baccarani, M.
;
Müller, M.
;
Li, J.
;
Parker, W.
;
Lustgarten, S.
;
Clackson, T.
;
Haluska, F.
;
Guilhot, F.
;
Kantarjian, H.
;
Soverini, S.
;
Hochhaus, A.
;
Hughes, T.
;
Rivera, V.
;
et al.
2012
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
Yin, O.
;
Giles, F.
;
Baccarani, M.
;
le Coutre, P.
;
Chiparus, O.
;
Gallagher, N.
;
Saglio, G.
;
Hughes, T.
;
Hochhaus, A.
;
Kantarjian, H.
;
Larson, R.
2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Hochhaus, A.
;
Saglio, G.
;
Larson, R.
;
Kim, D.
;
Etienne, G.
;
Rosti, G.
;
De Souza, C.
;
Kurokawa, M.
;
Kalaycio, M.
;
Hoenekopp, A.
;
Fan, X.
;
Shou, Y.
;
Kantarjian, H.
;
Hughes, T.
2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M.
;
Deininger, M.
;
Rosti, G.
;
Hochhaus, A.
;
Soverini, S.
;
Apperley, J.
;
Cervantes, F.
;
Clark, R.
;
Cortes, J.
;
Guilhot, F.
;
Hansen-Hjorth, H.
;
Hughes, T.
;
Kantarjian, H.
;
Kim, D.
;
Larson, R.
;
Lipton, J.
;
Mahon, F.
;
Martinelli, G.
;
Mayer, J.
;
Muller, M.
;
et al.
2012
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase
Larson, R.
;
Yin, O.
;
Hochhaus, A.
;
Saglio, G.
;
Clark, R.
;
Nakamae, H.
;
Gallagher, N.
;
Demirhan, E.
;
Hughes, T.
;
Kantarjian, H.
;
le Coutre, P.
2009
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value
Hochhaus, A.
;
Muller, M.
;
Radich, J.
;
Branford, S.
;
Kantarjian, H.
;
Hanfstein, B.
;
Rousselot, P.
;
Kim, D.
;
Lipton, J.
;
Bleickhardt, E.
;
Lambert, A.
;
Hughes, T.
Discover
Author
6
Gallagher, N.
6
Radich, J.
5
Branford, S.
5
Deininger, M.
5
Rosti, G.
4
Clark, R.
4
Druker, B.
4
et al.
4
le Coutre, P.
3
Blakesley, R.
.
< previous
next >
Subject
13
Benzamides
13
Piperazines
13
Pyrimidines
12
Humans
12
Imatinib Mesylate
11
Antineoplastic Agents
8
Leukemia, Myelogenous, Chronic, B...
8
Protein Kinase Inhibitors
8
Treatment Outcome
7
Fusion Proteins, bcr-abl
.
next >
Date issued
17
2010 - 2017
5
2003 - 2009